Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 5, 2004, Pages 1272-1277

  Roy, S ^a   Caillouette, J C ^a   Roy, T ^b   Faden, J S ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Food and Drug Administration ^*

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Estrogen therapy; Follicle stimulating hormone; Menopause; Vaginal pH value

Indexed keywords

ESTROGEN; FOLLITROPIN;

CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; COSTA RICA; DIAGNOSTIC PROCEDURE; EPIDEMIOLOGICAL DATA; FEMALE; FOLLICULAR PHASE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MENOPAUSAL SYNDROME; PH; PREDICTION; PRIORITY JOURNAL; REVIEW; SCREENING; STATISTICAL SIGNIFICANCE; VAGINA;

EID: 2542477876     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2003.12.015     Document Type: Article

References (35)

1. Cruickshank R, Sharman A. The biology of the vagina in human subjects: I, glycogen in the vaginal epithelium and its relation to ovarian activity; II, the bacterial flora and secretion of the vagina at various age-periods and their relation to glycogen in the vaginal epithelium; III, vaginal discharge of non-infective origin. J Obstet Gynaecol Br Empire 1934;41:190-207, 208-26, 369-84.
2. Center for Devices and Radiological Health. 510 (k) Premarket notification database [online]. Rockville, Md: U. S. Food and Drug Administration, 1996; no. K960648. Updated April 5, 2004. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cPMN/pmn.cfm?ID=91925.
3. Rein MF, Muller M. Trichomonas vaginalis and trichomoniasis. In: Holmes KK, Mardh P-A, Sparling PF, Wiesner PJ, Cates Jr, W, Lemon SM, et al, editors. Sexually transmitted diseases. 2nd ed. New York: McGraw-Hill; 1990. p. 481-92.
4. Smith KPB. Estrogens and the urogenital tract: studies on steroid hormone receptors and a clinical study on a new estradiol releasing vaginal ring. Acta Obstet Gynecol Scand 1993;72(suppl):S1-26.
5. Boskey ER, Telsch KM, Whaley KJ, Moench TR, Cone RA. Acid production of vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect Immun 1999;67:5170-5.
6. Rakoff AE, Feo LG, Goldstein L. The biological characteristics of the normal vagina. Am J Obstet Gynecol 1944;47:467-94.
7. Lang W. Vaginal acidity and pH: a review. Obstet Gynecol Surv 1955;10:546-60.
8. Gregoire AT, Kandil O, Ledger WJ. The glycogen content of human vaginal epithelial tissue. Fertil Steril 1971;22:64-8.
9. Stahl CE, Hill GB. Microflora of the female genital tract. In: Galask RP, Larsen B, editors. Infectious diseases in the female patient. New York: Springer-Verlag; 1986. p. 16-42.
10. Caillouette JC, Sharp CF, Zimmerman GJ, Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol 1997;176:1270-7.
11. Elia G, Bergman A. Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence. Obstet Gynecol Surv 1993;48:509-17.
12. Sweet R, ed. The vaginitis report [newsletters]. Vol 1. St. Paul, Minn: 3M National Vaginitis Association; 1997.
13. Schwebke JR. Guest presentation at the open meeting of the Center for Devices and Radiological Health, Gaithersburg, Md, 6-7 December 1999; CDRH transcript 3569t2. p. 87, lines 7-8. U. S. Food and Drug Administration website. Available at: http://www.fda.gov/ohrms/dockets/ac/cdrh99t.htm.
14. Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. Maturitas 1995;22:S31-3.
15. Semmens JP, Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA 1982;248:445-8.
16. Semmens JP, Tsai CC, Semmens EC, Loadhott CB. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol 1985;66:15-8.
17. Molander U, Milsom I, Ekelund P, Mellstrom D, Eriksson O. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. Maturitas 1990;12:113-20.
18. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107.
19. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-6.
20. Smith KPB. Estrogens and the urogenital tract: studies on steroid hormone receptors and a clinical study on a new estradiol releasing vaginal ring. Acta Obstet Gynecol Scand Suppl 1993;157:1-26.
21. Chomppootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsan N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. Clin Pharmacol Ther 1998;64:204-10.
22. Henriksson L, Stjernquist M, Boquist L, Alander L, Selinus I. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171:624-32.
23. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
24. Bachmann G. The estradiol vaginal ring: a study of existing clinical data. Maturitas 1995;22:S21-9.
25. Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause-cytology, histology and pH as methods of assessment. Maturitas 1995;21:51-6.
26. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with CEE vaginal cream in the treatment of postmenopausal urogenital atrophy. BJOG 1996;103:351-8.
27. Casper F, Petri E, Vaginal Ring Study Group. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Int Urogynecol J 1999;10:171-6.
28. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999;180:1072-9.
29. Ouslander JG, Cooper EBS, Godley D. Estrogen treatment for incontinence in frail older women. J Am Geriatr Soc 1999;47:1383-4.
30. Backer LC, Rubin CS, Marcus M, Kieszak SM, Schaber SE. Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). Menopause 1999;6:29-35.
31. Garcia-Closas M, Herrero R, Bratti C, Hildesheim A, Sherman ME, Morera LA, et al. Epidemiologic determinants of vaginal pH. Am J Obstet Gynecol 1999;180:1060-6.
32. Samsioe G. Urogenital aging: a hidden problem. Am J Obstet Gynecol 1998;178:8245-9.
33. Roy S, Caillouette JC, Roy T, Faden S, Ramos DE. Improving appropriate use of antifungal medications: the role of an over-the-counter vaginal pH self-test device. Infect Dis Obstet Gynecol 2003;11:209-16.
34. Benjamin F, Deutsch S. Immunoreactive plasma estrogens and vaginal hormone cytology in postmenopausal women. Int J Gynaecol Obstet 1980;17:546-50.
35. Stanczyk FZ, Chaikittisilpa S, Roy S. Pharmacologic deficiency in Women's Health Initiative Study. J Reprod Med 2003;48: 485-6.